- Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study. Zhou, K., Donnelly, L., Burch, L., Tavendale, R., Doney, A.S., Leese, G., Hattersley, A.T., McCarthy, M.I., Morris, A.D., Lang, C.C., Palmer, C.N., Pearson, E.R. Clin. Pharmacol. Ther. (2010)